MaaT Pharma receives positive DSMB review for Phase 3 trial of MaaT013 in acute Graft-versus-Host Disease.

M2 EQUITYBITES-October 26, 2023-MaaT Pharma receives positive DSMB review for Phase 3 trial of MaaT013 in acute Graft-versus-Host Disease

(C)2023 M2 COMMUNICATIONS http://www.m2.co.uk

Clinical-stage biotechnology company MaaT Pharma (Euronext Paris:MAAT) announced on Thursday that the Data Safety Monitoring Board (DSMB) has unanimously recommended the continuation of the open-label, single-arm pivotal Phase 3 clinical trial, ARES, assessing MaaT013 in acute Graft-versus-Host Disease (aGvHD).

A review by the DSMB examined the trial's safety, efficacy and protocol adherence, and affirmed a favourable benefit/risk ratio, characterising MaaT013 as having "high efficacy and low toxicity" in the patient population. The Overall Response Rate (ORR) exceeded pre-defined protocol assumptions, reinforcing confidence in the trial.

The DSMB's assessment of safety validated that there were no safety concerns based on data from 30 reviewed patients. MaaT013...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT